

Serial No. 10/805,860

REMARKS

After entry of this amendment, claims 1-10 are currently pending. Claim 9 has been amended. Support for the amended recitation "therapeutically effective amount" of claim 9 can be found throughout the specification, *inter alia*, at page 9, lines 18-19. No new matter is added.

Rejections under 35 U.S.C. §112

Claim 9 is rejected under 35 U.S.C. §112, second paragraph, as being indefinite. According to the Examiner, claim 9 is self-conflicting because it is drawn to a pharmaceutical composition without a dosage limitation.

Applicants have amended claim 9 according to the Examiner's suggestion to include the limitation "therapeutically effective amount". Thus, this rejection have been overcome.

Allowable Subject Matter

Applicants acknowledge the Examiner's determination that claims 1-10 limited to compounds of formula I where X=N; Y=S; R2 is as defined and A/R1 are nonheterocyclic are allowable.

CONCLUSION

In light of the above amendments and remarks, Applicants submit that all of the rejections have been overcome and must be withdrawn. Further, Applicants submit that the application is now in form for issuance and an early allowance is earnestly requested. If any issues remain, the Examiner is invited to telephone the Attorney at the number below.

Respectfully submitted,


Susan K. Pocchiari
Attorney for Applicant(s)
Reg. No. 45,016

Date: April 21, 2005

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-5648